Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind non-inferiority trial of human fibrinogen in chronic liver disease patients with acquired hypofibrinogenemia
CTR20252908Phase 3Active
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Fibrinogen human in Acquired fibrinogenopenia (2 arms), sponsored by Shanxi Kangbao Biological Products. Primary endpoints: Hemostatic success rate and Activity recovery rate. Started Sep 2025; status: active.
02
Drugs
Fibrinogen human
03
Conditions
Acquired fibrinogenopenia
Beyond the preview
Go deeper on CTR20252908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252908.